Fortress Biotech, Inc. (FBIOP) Gross margin 2016–2025
Fortress Biotech, Inc. (FBIOP) gross margin by fiscal year — reported gross profit divided by reported revenue.
66.9%FY2025 · since FY2016: 95.2% → 66.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 66.9% | +3.1 pp |
| FY2024 | 63.8% | -9.1 pp |
| FY2023 | 72.9% | +13.5 pp |
| FY2022 | 59.4% | +6.0 pp |
| FY2021 | 53.4% | -14.6 pp |
| FY2020 | 68.0% | -3.3 pp |
| FY2019 | 71.2% | -6.0 pp |
| FY2018 | 77.2% | -1.6 pp |
| FY2017 | 78.8% | -16.4 pp |
| FY2016 | 95.2% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More FBIOP financial trends
FBIOP RevenueFBIOP Net incomeFBIOP Net marginFBIOP Gross profitFBIOP Operating incomeFBIOP Operating marginFBIOP Operating cash flowFBIOP Free cash flowFBIOP Capital expendituresFBIOP Return on equityFBIOP Stock buybacksFBIOP Dividends paidFBIOP Total assetsFBIOP Total liabilitiesFBIOP Shareholders’ equityFBIOP overview →